J.P. Morgan
January43rd Annual14,Healthcare2025 Investment Conference
Olivier Loeillot
President and Chief Executive Officer
January 14, 2025
Who is Repligen?
3
Repligen Snapshot: Innovation Leader in Bioprocessing
- Supporting Pharma and CDMO's with a broad and differentiated portfolio of hardware & consumables used in their biological drug production
- Innovation engine … disrupting norms with fast-to-market products that enable yield gains and cost efficiencies
- Global manufacturing presence with
security of supply | >1,700 |
employees |
- ~65% clinical, 35% commercial
- Revenue majority mAb-based (~80%); strong and growing presence in new modalities (~20%)
Performing Above Market
-
14 disruptive product launches … organic
R&D and 14 acquisitions since 2014 - 19% 5-year revenue CAGR
$630 - 639M | |||
Analytics +2x | |||
Proteins steady | |||
Chrom +2x | |||
$270M | Filtration +3x | ||
2019 2024e
We are 10 Years "Young" … And Fit for Growth!
4
2024 Business Highlights
2-3% | ~80% |
Revenue Growth | 2024e Revenue from Highly |
ex-COVID | Differentiated Products |
Filtration, Chrom & | Examples: |
Analytics 6-7% | XCell® ATF |
New Modalities up 10% | OPUS® Pre-Packed Columns |
RPM-enabled RS TFF | |
50%+ probability funnel | Launched 3 key new |
up >15% at YE24 | products in 2024 |
~ +100 bps | M&A | 68% |
Gross Margin | Executing with Strict | Reduction in Scope 2 |
Expansion | Criteria | Emissions |
Net price realization | Tantti acquisition … | 88% global electricity |
base matrix enables | usage powered by | |
Strong execution of | full resin capabilities | 100% renewable |
manufacturing RPS | ||
Operating expense | Successful integration | 3rd Sustainability |
management | of Metenova | report published |
*Sustainability Data is | ||
for year 2023 | ||
Solid performance in a challenging year
5
Strong End Markets with Positive Trends Entering 2025
mAb-based
Therapeutics ~$250B
Most mature,
largest, steady Market 2024e
~$15B
Biosimilar mAbs
Rapidly expanding | ~$15B |
subset | |
New | |
Modalities | ~$16B |
Youngest, | |
fastest growing |
8-10% Projected CAGR
184 US FDA approvals ~2K Ph 1-3 clinical pipeline
>20% Projected CAGR
43 US FDA approvals >150 Ph 1-3 clinical pipeline
>30% Projected CAGR
29 US FDA approvals
>3K in development pipeline
Market Trends
- Biopharma market growing HSD with aging population
- Majority of R&D pipeline in new modalities
- Development and manufacturing costs under more scrutiny
- Local governments pushing for localization
- U.S. biggest region for sales, APAC for trials
- Generative AI already playing a key role in drug discovery and beyond
US FDA approval data as of Jan. 6, 2025 Projected CAGR is for 4-year period from proprietary research reports
6
Broad Portfolio Across the Bioproduction Workflow; Addressing Pain Points
Broad Portfolio Across the Bioproduction Workflow; Addressing Pain Points
How are we Different?
Our approach to winning through differentiation
9
Repligen's Value Creation Equation
StrategyCapabilities
Results: 2014 to 2024e
- 100% Bioprocessing including Analytics
- Disruptive technology launches
to generate productivity gains
- Extensive portfolio across mAbs and new modalities workflows
- Disciplined M&A with strong return creates differentiation
- Innovation enabling customer efficiency
- Our culture … nimble,
collaborative, transparent
- Commercial & Operations excellence
- Fit for Growth … talent, expertise, process rigor
- 10-foldincrease in revenue
- Adj. EPS $0.24 to $1.54
- 3-foldincrease in TAM
- Market cap ~$600M to ~$9B
Confidence in our ability to grow above market and expand margin over the next 5 years
Adj. EPS 2024e reflects midpoint of guidance provided Nov. 12, 2024
10
Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |
Attachments
- Original document
- Permalink
Disclaimer
Repligen Corporation published this content on January 18, 2025, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 18, 2025 at 19:04:01.621.